Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.

Muti P, Secreto G, Krogh V.

Breast Cancer Res Treat. 2017 Jun;163(3):631-632. doi: 10.1007/s10549-017-4194-8. Epub 2017 Mar 18. No abstract available.

PMID:
28315966
2.

Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.

Figg WD 2nd, Cook K, Clarke R.

Cancer Biol Ther. 2014;15(12):1586-7. doi: 10.4161/15384047.2014.972783. Review.

3.

Adjuvant hormonal therapy for premenopausal women with breast cancer.

Emens LA, Davidson NE.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):486S-94S.

4.

Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.

Hubalek M, Brantner C, Marth C.

Wien Med Wochenschr. 2010 Apr;160(7-8):167-73. doi: 10.1007/s10354-010-0771-8.

PMID:
20473727
5.

Adjuvant endocrine treatment in premenopausal early breast cancer.

Orlando L, Fedele P, Cinefra M, Sponziello F, Calvani N, Chetrì MC, Rizzo P, D'Amico M, Schiavone P, Portaluri M, Criscuolo M, Burlizzi S, Cinieri S.

Oncology. 2009;77 Suppl 1:9-13. doi: 10.1159/000258490. Epub 2010 Feb 2. Review.

PMID:
20130426
6.

Adjuvant endocrine therapy for premenopausal women: Type and duration.

Francis PA.

Breast. 2017 Aug;34 Suppl 1:S108-S111. doi: 10.1016/j.breast.2017.06.040. Epub 2017 Jun 29.

PMID:
28669713
7.

Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.

Chlebowski RT, Pan K, Col NF.

Breast Cancer Res Treat. 2017 Jan;161(2):185-190. doi: 10.1007/s10549-016-4024-4. Epub 2016 Oct 26. Review.

PMID:
27785653
8.

Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.

Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A.

Breast Cancer Res Treat. 2010 Aug;123(1):303-10. doi: 10.1007/s10549-010-0794-2. Epub 2010 Feb 27.

9.

Controversies in adjuvant endocrine treatment of premenopausal women.

Goldstein LJ.

Clin Breast Cancer. 2006 Feb;6 Suppl 2:S36-40. Review.

PMID:
16595024
10.

Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings.

McDonald Wade S 3rd, Hackney MH, Khatcheressian J, Lyckholm LJ.

Oncology. 2008;75(3-4):192-202. doi: 10.1159/000163059. Epub 2008 Oct 8. Review.

PMID:
18841034
11.

Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.

Colleoni M, Munzone E.

Drugs. 2015 Aug;75(12):1311-21. doi: 10.1007/s40265-015-0433-7. Review.

PMID:
26177891
12.

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.

Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O.

Ann Oncol. 2017 Sep 1;28(9):2225-2232. doi: 10.1093/annonc/mdx285.

13.

Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.

Mathew A, Davidson NE.

Breast. 2015 Nov;24 Suppl 2:S120-5. doi: 10.1016/j.breast.2015.07.027. Review.

PMID:
26255743
14.

Adjuvant hormonal therapy for premenopausal women with breast cancer.

Brown RJ, Davidson NE.

Semin Oncol. 2006 Dec;33(6):657-63. Review.

PMID:
17145345
15.

Adjuvant endocrine therapy in premenopausal women with operable breast cancer: understanding the issues.

Goldhirsch A, Price KN.

Oncology (Williston Park). 2010 Apr 15;24(4):331-2. No abstract available.

16.
17.

Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.

Ozaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T.

Breast Cancer. 2018 May;25(3):343-349. doi: 10.1007/s12282-018-0836-x. Epub 2018 Jan 22.

18.

Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.

Montemurro F, Del Mastro L, De Laurentiis M, Puglisi F.

Expert Rev Anticancer Ther. 2016;16(2):211-8. doi: 10.1586/14737140.2016.1128327. Epub 2015 Dec 23. Review.

PMID:
26634955
19.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

20.

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA; International Breast Cancer Study; GroupSOFT and TEXT Investigators.

Breast. 2013 Dec;22(6):1094-100. doi: 10.1016/j.breast.2013.08.009. Epub 2013 Oct 2.

Supplemental Content

Support Center